Module 2: Discussion + Responses – DB Group 3 From MSN-671-001-2022-030

Online Discussion

Pharmacogenomic (PGx) testing is a “hot topic” and you will quickly realize clinicians have varied opinions and practices regarding its use. Take a second to explore some of the websites of the major pharmacogenetic companies, Genomind (Link (Links to an external site.)), Genelex (Link (Links to an external site.)) and GeneSight (Link (Links to an external site.)). Then, visit the American Academy of Child & Adolescent Psychiatry’s website (Link (Links to an external site.)) & (Link (Links to an external site.)), which also explains the testing. Notice the difference in how the information is presented.

*For this discussion, you will answer the question which corresponds to the FIRST letter of your FIRST name.

*Then you will respond to the main postings of at least two of the other learners who have answered questions different from yours.

Prompt:

You will take one side of the “debate” regarding the utility of pharmacogenomic testing in the clinical setting.

  • If your FIRST name begins with A-M: Explain the benefits of pharmacogenomic testing. Regardless of your personal opinion, take the “pro” side of the argument and find evidence to support why more clinicians should be using this in their practice.
  • If your FIRST name begins with N-Z: Explain the disadvantages of pharmacogenomic testing. Regardless of your personal opinion, take the “con” side of the argument and find evidence to support why clinicians should reconsider using this in their practice, or not use it all.

Recall that your main posting should be submitted by Wednesday at 23:59, EST. All responses to other learners discussion questions must be submitted no later than Sunday at 23:59, EST in order to be considered for grading purposes.

Get 15% discount on your first order with us
Use the following coupon
FIRST15

Order Now